Octreotide acetate in dominant cystoid macular dystrophy

European Journal of Ophthalmology

Volumn 18, Issue 1, 2008, Pages 99-103

  Hogewind, Barend F ^a   Pieters, G ^a   Hoyng, C B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cystoid macular edema; Dominant cystoid macular dystrophy; Humans; Octreotide

Indexed keywords

OCTREOTIDE;

ADOLESCENT; ADULT; ARTICLE; AUTOSOMAL DOMINANT INHERITANCE; CASE REPORT; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INFORMED CONSENT; MALE; OPHTHALMOLOGY; PRIORITY JOURNAL; RETINA MACULA CYSTOID EDEMA; RETINA MACULA DEGENERATION; TREATMENT DURATION; VISUAL ACUITY;

EID: 41149141513     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210801800117     Document Type: Article

References (16)

1. Deutman AF, Pinckers AJ, Aan de Kerk AL. Dominantly inherited cystoid macular edema. Am J Ophthalmol 1976; 82: 540-8.
2. Kremer H, Pinckers AJ, van den Helm B, Deutman AF, Ropers HH, Mariman EC. Localization of the gene for dominant cystoid macular dystrophy on chromosome 7p. Hum Mol Genet 1994; 3: 299-302.
3. Pinckers A, Marre M. Basic phenomena in acquired colour vision deficiency. Doc Ophthalmol 1983; 55: 251-71.
4. Scorolli L, Morara M, Meduri A, et al. Treatment of cystoid macular edema in retinitis pigmentosa with intravitreal triamcinolone. Arch Ophthalmol 2007; 125: 759-64.
5. van Hagen PM, Baarsma GS, Mooy CM, et al. Somatostatin and somatostatin receptors in retinal diseases. Eur J Endocrinol 2000; 143: S43-51.
6. Funatsu H, Yamashita H, lkeda T, Mimura T, Eguchi S, Hori S. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2003; 110: 1690-6.
7. Tranos PG, Wickremasinghe SS, Stangos NT, Topouzis F, Tsinopoulos I, Pavesio CE. Macular edema. Surv Ophthalmol 2004; 49: 470-90.
8. Kuijpers RW, Baarsma S, van Hagen PM. Treatment of cystoid macular edema with octreotide. N Engl J Med 1998; 338: 624-6.
9. Chantelau E, Frystyk J. Progression of diabetic retinopathy during improved metabolic control may be treated with reduced insulin dosage and/or somatostatin analogue administration - a case report. Growth Horm IGF Res 2005; 15: 130-5.
10. Kafkala C, Choi JY, Choopong P, Foster CS. Octreotide as a treatment for uveitic cystoid macular edema. ARVO 2005 abstract. Invest Ophthalmol Vis Sci 46: abstract 2850.
11. van Velthoven M, Verbraak F, Boxer A, Pedro J, de Smet M. Volumetric and topographic measurement in patients with cystoid macular edema using a combined SLO-OCT ophthalmoscope. ARVO 2003 abstract. Invest Ophthalmol Vis Sci 44: abstract 3623.
12. Shah SM, Haller JA, Campochiaro PA, Polito A, Nguyen QD, Vitale S. A randomised, prospective, controlled clinical trial of sandostatin LAR depot in patients with cystoid macular edema. ARVO 2003 abstract. Invest Ophthalmol Vis Sci 43: abstract 4310.
13. Missotten T, Baarsma GS, Kuijpers RW, et al. Somatostatin-related therapeutics in ophthalmology: a review. J Endocrinol Invest 2005; 28: 118-26.
14. Grant MB, Caballero S Jr. The potential role of octreotide in the treatment of diabetic retinopathy. Treat Endocrinol 2005; 4: 199-203.
15. Katz MD, Erstad BL. Octreotide, a new somatostatin analogue. Clin Pharm 1989; 8: 255-73.
16. Maminishkis A, Jalickee S, Miller SS. Somatostatin (SST14) enhances retinal reattachment of experimentally produced subretinal space (SRS) blebs in vivo. ARVO 2002 abstract. Invest Ophthalmol Vis Sci 43: abstract 4541.